CN109913554A - A kind of lncRNA marker relevant to breast cancer - Google Patents
A kind of lncRNA marker relevant to breast cancer Download PDFInfo
- Publication number
- CN109913554A CN109913554A CN201910298612.6A CN201910298612A CN109913554A CN 109913554 A CN109913554 A CN 109913554A CN 201910298612 A CN201910298612 A CN 201910298612A CN 109913554 A CN109913554 A CN 109913554A
- Authority
- CN
- China
- Prior art keywords
- linc01522
- breast cancer
- expression
- gene
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of lncRNA marker relevant to breast cancer, the marker is LINC01522.The expression up-regulation that the invention discloses LINC01522 in patient with breast cancer, the expression by detecting LINC01522 may determine that whether subject suffers from breast cancer, while by targeting LINC01522, reduce the horizontal stretcher breast cancer of LINC01522.
Description
Technical field
The invention belongs to biomedicine fields, are related to a kind of lncRNA marker relevant to breast cancer, the marker
For LINC01522.
Background technique
Breast cancer has become the Major health problems in China or even the whole world as the most common malignant tumour of women.Root
According to gene expression profile, breast cancer is divided into five kinds of hypotypes by Perou et al.: human epidermal growth factor acceptor -2 (HER-2) crosses table
Up to type, substrate template breast cancer, Luminal A type, Luminal Type B, and tumour similar with normal tissue (Ferlay J,
Soerjomataram I,Ervik M,et al.GLOBOCAN 2012:Estimated Cancer Incidence,
Mortality and PrevalenceWorldwide in 2012,Vol.2015,2015.).In all hypotypes of breast cancer,
Luminal Type B breast cancer proportion highest, China have in recent years shared by the studies have shown that Luminal Type B breast cancer of part
Ratio be 47.7% and 52.8%.Other than disease incidence is higher, there are also hormone receptor low expressions for Luminal Type B breast cancer
(Kenyon M,Mayer D K,Owens A K.Late and long-term effects of breast
cancertreatment and surveillance management for the general practitioner[J].J
ObstetGynecol Neonatal Nurs, 2014,43 (3): 382-398.), amplified gene (MKI67) and cell cycle phase
(CCNB 1 and MYBL2 express the features such as higher, histological grade is higher to correlation gene.
Luminal Type B breast cancer is made of two kinds of hypotypes of HER-2 positive type and HER-2 negative type, is a kind of heterogeneous
Disease.Treatment for Luminal Type B breast cancer, it should more focus on comprehensive, individuation and precision.It should be according to every
The pathological characteristic of position patient with breast cancer, selects correct treatment means.The treatment of breast cancer includes local treatment and systemic therapy,
Wherein local treatment divides operative treatment, radiotherapy etc., and systemic therapy includes a body chemotherapy, endocrine therapy and more targeted
Targeted therapy.
In recent years, as high throughput gene sequence and biochip technology are the study found that in human genome only about
Having 2% gene order has the ability of encoding function albumen, remaining 90% is referred to as non-coding RNA (non-coding
RNA,ncRNA).LncRNA had once been considered as " dark matter " of genetic transcription because not encoding polypeptide, with more and more
LncRNA is found, its function is also gradually examined and released: lncRNA has multiple binding site molecule points, can influence specific gene
Expression come regulatory protein binding factor activity；LncRNA, which can act on rna plymerase ii etc., influences epigenetics, is contaminating
Chromaticness modification, the vital movement for adjusting many-sided regulating cell such as transcriptional level and post-transcriptional level.Fresh evidence table in recent years
Bright, lncRNA can activate PI3K/AKT, and the signal paths such as TGF-p are participated in by the carcinogenic of modulate tumor or suppression cancer approach
In the process of tumour.Since many kinds of and binding mode of lncRNA is various, their effect machines in tumor development
System is still not clear, it has also become the new research hotspot after miRNAs.
It needs to find more accurate, more tumor markers and therapy target at this stage, improves traditional cancer assessment
Method is that Individualized program is formulated in the treatment of breast cancer, assesses curative effect, predict prognosis.
Summary of the invention
In order to make up for the deficiencies of the prior art, the purpose of the present invention is to provide a kind of relevant to breast cancer occurrence and development
The application of biomarker and the marker in breast cancer diagnosis and treatment, is more specifically examined in Luminal Type B breast cancer
Application in disconnected and treatment.
To achieve the goals above, the present invention adopts the following technical scheme:
The present invention provides the applications of LINC01522, are used to prepare the product of Diagnosis of Breast cancer.
Further, the product includes the reagent for detecting LINC01522 expression in sample.
Further, the reagent includes by reverse transcription PCR, real-time quantitative PCR, in situ hybridization, chip technology detection
The reagent of LINC01522 expression.
Further, the breast cancer is Luminal Type B breast cancer.
Further, the reagent with Real-time quantitative PCR detection LINC01522 expression includes specific amplification
The primer of LINC01522.
Further, the primer sequence of specific amplification LINC01522 is as shown in NO.1~2 SEQ ID.
The present invention provides a kind of products of Diagnosis of Breast cancer, including chip or kit, wherein the chip or reagent
Box includes the reagent for detecting LINC01522 expression.
Further, the reagent for LINC01522 expression being detected in chip includes specific recognition LINC01522 gene
Probe；The reagent that LINC01522 expression is detected in kit includes primer or the spy of specific amplification LINC01522 gene
The probe of opposite sex identification LINC01522 gene.
Further, the primer sequence of specific amplification LINC01522 gene is as shown in NO.1~2 SEQ ID.
The present invention provides the applications of LINC01522, for constructing the computation model of prediction breast cancer.
The present invention provides the applications of LINC01522, for screening the drug candidate for the treatment of breast cancer.
The present invention provides the applications of LINC01522, are used to prepare the pharmaceutical composition for the treatment of breast cancer.
Further, described pharmaceutical composition includes the inhibitor of LINC01522.
Detailed description of the invention
Fig. 1 is the expression figure using QPCR detection LINC01522 gene in breast cancer tissue.
Specific embodiment
The present invention after extensive and in-depth study, by the method for high-flux sequence, detects in breast cancer sample
LncRNA has found lncRNA wherein with obvious differential expression, inquires into itself and cream in the expression of tumor tissues and normal tissue
Relationship between the generation of gland cancer, to find better approaches and methods for the diagnosis of breast cancer and targeted therapy.Pass through sieve
Choosing prompts LINC01522 to can be used as breast cancer present invention firstly discovers that LINC01522 is significantly raised in breast cancer tissue
Diagnosis marker and therapeutic targets.
Term " LINC01522 " is located on No. 20 chromosomes, gene I/D 101927457, including LINC01522 gene and
Its homologue, mutation and isoform.The term covers overall length, unprocessed LINC01522, and from processing in cell
Any type of LINC01522.The term covers the natural generation variant of LINC01522, and (such as splice variant or equipotential become
Body).The term covers such as LINC01522 gene, the gene order (NR_110027.1) of people LINC01522, and comes from and appoint
What its vertebrate origin.
It will be appreciated by those skilled in the art that the means of measurement gene expression are not importances of the invention.It can be
The expression of biomarker is detected on transcriptional level.The present invention can use any method known in the art measurement base
Because of expression.
As used in this article, term " marker " " biomarker " refers to specific biological characteristic, bioid
The molecular indicator for learning feature or aspect can be used for determining presence or absence of specified disease or situation and/or specific disease
The severity of disease or situation.Marker in the present invention refers to can detect and the index including such as LINC01522 in the sample
Molecule or elements collection (such as predicting, diagnosis and/or prognostic indicator).Biomarker can be prediction biomarker and
It serves as with specified disease or illness.Biomarker include but is not limited to polynucleotides (such as DNA and/or RNA (such as
MRNA)), polynucleotide copies number changes (such as DNA copy number).
As used in this article, " amount " of biomarker or "horizontal" are the detectable levels in biological sample.This
It can be measured a bit by well known by persons skilled in the art and the methods disclosed herein.
Terms used herein " differential expression " indicates to mark with one or more present invention biologies identical in second of sample
The expression of will object compares, after measured the amount or level of RNA, one or more biological markers of the invention in a sample
The difference of one or more splice variant expressions of the RNA of the object and/or biomarker RNA.Differential expression can be with
It is as described herein and those skilled in the art understand that method determine.Term " differential expression " or " variation of expression " indicate
With given in second of sample biomarker measure expression compared with, the amount of RNA after measured gives biology in sample
Marker can measure increasing or decreasing for expression.Term " differential expression " or " variation of expression " also may indicate that with
The expression that measures of biomarker compares in second sample group, and biomarker is given in sample group can measure expression
Horizontal increases or decreases." differential expression " used herein can be with the expression of given biomarker relative in control
The ratio of the Average expression level of given biomarker is measured, and wherein ratio is not equal to 1.0.It can also be measured with p value
Differential expression.When using p value, when p value is less than 0.1, biomarker is accredited as the difference between the first and second groups
Expression.More preferable p value is less than 0.05.Even more preferably p value is less than 0.01.Even more preferably from p value less than 0.005.Most preferably p value is small
In 0.001.When sketch-based user interface determines differential expression, if in the first and second sample the ratio of expression be greater than or
Less than 1.0, then RNA is differential expression.For example, the ratio greater than 1.2,1.5,1.7,2,3,4,10,20, or less than 1
Ratio, such as 0.8,0.6,0.4,0.2,0.1,0.05.In another embodiment of the present invention, if first group
The ratio of Average expression level and the Average expression level of the second group is more than or less than 1.0, then transcribed nucleic acid is originally difference table
It reaches.For example, the ratio greater than 1.2,1.5,1.7,2,3,4,10,20, or the ratio less than 1, for example, 0.8,0.6,
0.4,0.2,0.1,0.05.In another embodiment of the present invention, if expression and second in first sample
In group the ratio of Average expression level be more than or less than 1.0, for example including ratio be greater than 1.2,1.5,1.7,2,3,4,10,
20 or ratio less than 1, such as 0.8,0.6,0.4,0.2,0.1,0.05, then transcribed nucleic acid is originally differential expression.
" differential expression increase " or " up-regulation " indicates gene relative in contrast, and gene expression is (with rna expression or albumen
Matter expression measurement measurement) display increase at least 10% or more, such as 20%, 30%, 40% or 50%, 60%, 70%,
80%, 90% or more or 1.1 times, 1.2 times, 1.4 times, 1.6 times, 1.8 times or more.
" differential expression reduction " or " downward " indicates gene relative in contrast, and gene expression is (with rna expression or albumen
Matter expression measurement) display reduce at least 10% or more, such as 20%, 30%, 40% or 50%, 60%, 70%, 80%,
90% or less than 1.0 times, 0.8 times, 0.6 times, 0.4 times, 0.2 times, 0.1 times or less gene.For example, up-regulation gene include with
The expression of the RNA or albumen that separate from normal individual are compared, the RNA from the sample of the individual separation characterized by with breast cancer
Or the increased gene of protein expression level.For example, down-regulated gene includes compared with the sample separated from normal individual, to suffer from
The gene that RNA or protein expression level reduce in the sample for the individual separation that breast cancer is characterized.
In the present invention, LINC01522 has increased expression in patient with breast cancer.
Chip, kit
The present invention provides the product of the expression of LINC01522 gene in detection, the product includes (but unlimited
In) chip or kit.Wherein chip includes: solid phase carrier；And orderly it is fixed on the oligonucleotides on the solid phase carrier
Probe, the oligonucleotide probe some or all of specifically correspond to shown in LINC01522 sequence.
The solid phase carrier includes inorganic carrier and organic carrier, the inorganic carrier include but is not limited to have silicon carrier,
Glass carrier, ceramic monolith etc.；The organic carrier includes polypropylene film, nylon membrane etc..
As used herein, " oligonucleotides " refers generally to short, and single-stranded polynucleotides are less than about in length
250 nucleotide, but it's not necessary.Oligonucleotides can be synthesis.Term " oligonucleotides " and " polynucleotides " are simultaneously
It is not mutually exclusive.Description above for polynucleotides is same and is applicable to oligonucleotides completely.
Term " probe " refers to can be with the molecule in conjunction with the particular sequence of another molecule or subsequence or other parts.Unless another
It points out, term " probe " is often referred to match and another polynucleotides (often referred to as " target polynucleotide ") by complementary base
In conjunction with polynucleotide probes.Lack sufficient sequence complementarity according to the stringency of hybridization conditions, probe energy and with the probe
Target polynucleotide combines.Probe can make direct or indirect label, and range includes primer.Crossing system, including, but it is unlimited
In: solution phase, solid phase, mixed phase or in situ hybridization measuring method.
As probe, fluorescent marker, radio-labeled, biotin labeling etc. can be used, cancer detection is carried out with polynucleotides
The label probe of label.Labeling method of polynucleotides itself is well known.Can check by the following method in sample whether
There are subject nucleic acids: fixed subject nucleic acid or its amplified matter are hybridized with label probe, are washed, and then measurement with
The label of solid phase binding.Alternatively, cancer detection polynucleotides can be also fixed, subject nucleic acid is hybrid with it, then application mark
The detections such as note probe are incorporated into the subject nucleic acid in solid phase.In this case, the cancer detection multicore glycosides being incorporated into solid phase
Acid is also referred to as probe.It the use of the method for polynucleotide probes measurement subject nucleic acid in this field is also well known.Can as follows into
Row this method: connect polynucleotide probes and subject nucleic acid (preferably within ± 4 DEG C) at or near Tm
Touching is washed, the label probe or the template nucleic acid in conjunction with solid phase probe for then measuring hybridization for hybridizing.
The polynucleotides used as probe be preferably sized to 18 or more nucleotide, more preferably 20 or
The overall length or less of more nucleotide and coding region.As primer in use, the polynucleotides are preferably sized to 18
Or more nucleotide and 50 or more Oligonucleotide.These probes have mutual with the specific base sequence of target gene
The base sequence of benefit.Here, so-called " complementation ", as long as hybridization, can not be complete complementary.These polynucleotides are usual
Have 80% or more, preferably 90% or more, more preferable 95% or more, particularly preferred 100% relative to the specific base sequence
Homology.These probes can be DNA, be also possible to RNA, furthermore it is possible to be logical in part of it or whole nucleotides
Cross the polynucleotides that the artificial replacement nucleic acid such as PN, LNA, ENA, GNA, TNA obtains.
Term " primer " refers to short nucleic acid sequences, as the nucleic acid sequence with short free 3 ' terminal hydroxyls (free 3 ' hydroxyls)
Column, it can form base-pair (basepair) with complementary template (template) and serve as the starting point of duplication template.In this hair
In bright, esophageal squamous cell carcinoma prognosis can be predicted in the following manner: by carrying out the ariyoshi using label polynucleotides of the invention
With the PCR amplification of antisense primer, whether required product is generated.Based on content modification PCR condition known in the art and can have
The length of adopted primer and antisense primer.
Kit of the invention includes the reagent for detecting LINC01522 gene, one or more substances selected from the group below: is held
Device, operation instructions, positive control, negative control object, buffer, auxiliary agent or solvent.
In kit of the invention can also have kit operation instructions, be described how using kit into
Row detection, and how tumor development to be judged using testing result, therapeutic scheme is selected.
The component of kit can pack in the form of aqueous medium or in the form of freeze-drying.Container appropriate in kit
It include typically at least a kind of bottle, test tube, flask, PET bottle, syringe or other containers, wherein a kind of component can be placed, and
And preferably, suitably equal part can be carried out.There are more than one group timesharing in kit, generally also will include in kit
Second, third or other additional containers, wherein being positioned separately additional component.However, the component of various combination can be wrapped
It is contained in a bottle.Kit of the invention will include generally also a kind of container for being used to accommodate reactant, seal to be used for
Commercial distribution.This container may include the plastic containers of injection molding or blowing mould, wherein can retain required bottle.
The present invention provides application of the LINC01522 in the computation model of preparation prediction breast cancer.As knack
What personnel can be appreciated that, the measurement of two or more markers can be used to improve the diagnosis problem in investigation.Biochemistry mark
Will object can measure individually, or in one embodiment of the invention, they can be measured simultaneously, for example, using chip or
Array technique based on pearl.Then the independent concentration for interpreting biomarker, such as using individual retentions of every kind of marker, or
Their combinations of person are interpreted.
In the present invention, it can be implemented in various ways marker levels and certain possibility or risk association and realize
The step of getting up.Preferably, the mathematically measurement concentration of combination gene and one or more other markers, and by combined value
It associates with basic diagnosis problem.It can be by any suitable prior art mathematical method by the measurement group of marker levels
It closes.
Inhibitor
In the present invention, the inhibitor of LINC01522 is selected from: using LINC01522 or its transcript as target sequence and can
Inhibit the disturbing molecule of LINC01522 gene expression or genetic transcription, comprising: shRNA (children purpura nephritis), siRNA
(siRNA), dsRNA, Microrna, antisense nucleic acid, or can express or be formed the shRNA, siRNA, dsRNA, small
The construction of RNA, antisense nucleic acid.
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, or according to the normal condition proposed by manufacturer.
Embodiment 1 screens gene marker relevant to breast cancer
1, sample collection
The cancerous tissue and corresponding normal tissue sample for collecting 4 Luminal Type B breast cancer respectively are (apart from tumour side
5 centimeters of edge), high-flux sequence is carried out, all patients are preoperative not to carry out chemotherapy, radiotherapy and endocrine therapy, and all patients are equal
Informed consent, the acquirement of above-mentioned all samples pass through the agreement of the committee, organizational ethics, and patient information is as shown in table 1.
1 sample information of table
2, the preparation and quality analysis of RNA sample
Total tissue RNA is extracted using TRIZOL method
1) it is shredded with scissors tissue, 1ml Trizol is added, shakes 1min on oscillator；Room temperature 10min makes core egg
Lean type is decomposed completely.
2) 200 μ l chloroforms (chloroform) are added, cover tightly pipe lid, acutely shake 15s, room temperature stands 10min.
3) 4 DEG C, 11000rpm is centrifuged 15min.
4) water sample layer is transferred in a new centrifuge tube, 500 μ l isopropanols is added；After being mixed by inversion, room temperature is stood
10min。
5) 4 DEG C, 11000rpm is centrifuged 15min.
6) liquid is carefully siphoned away with rifle, stays and is deposited in tube bottom, the ethyl alcohol of 1ml 75% is added, shakes 5s on the oscillator,
Washing precipitating is primary.
7) 4 DEG C, 8000rpm is centrifuged 5min.
8) supernatant is carefully removed, drying precipitated 10min, suitable water dissolution precipitating 10min is added.
9) RNA concentration is detected, identifies the yield and purity of RNA.
3, the building and sequencing of cDNA library
1) total serum IgE DNaseI digests: using DNA fragmentation present in DNase I digestion Total RNA sample, magnetic bead is pure
Change recycling reaction product, is finally dissolved in DEPC water；
2) rRNA: the good Total RNA sample of cancellationization is removed, is removed using the Ribo-Zero kit of Epicentre
RRNA carries out Agilent 2100 after removal and detects, verifies rRNA removal effect；
3) RNA is interrupted: taking previous step sample, addition interrupts Buffer, is placed in progress heat in PCR instrument and interrupts, interrupts
140-160nt；
4) synthesis of one chain of reverse transcription: appropriate primer being added into the sample after interrupting, after mixing well
Thermomixer thermophilic reacts certain time, is allowed to open secondary structure and in conjunction with primer, adds the chain prepared in advance
Synthetic reaction system Mix synthesizes a chain cDNA by corresponding program in PCR instrument；
5) synthesis of two chain of reverse transcription: preparing two chain synthesis reaction systems, one timing of thermophilic reaction on Thermomixer
Between, synthesis has the two chain cDNA of dUTP, and reaction product carries out purification and recovery with magnetic bead；
6) end is repaired: being prepared end and is repaired reaction system, thermophilic reacts certain time in Thermomixer, in enzyme
Under the action of, the cohesive end for the cDNA double-strand that reverse transcription obtains is repaired, end reparation product is purified with magnetic bead
Recycling, is finally dissolved in EB Solution for sample；
7) 3 ' end cDNA adds " A ": it prepares and adds " A " reaction system, thermophilic reacts certain time in Thermomixer,
Under the action of enzyme, 3 ' ends for the product cDNA for repairing end are plus A base；
8) connection of 5 ' adapter of cDNA: preparing connector coupled reaction system, the thermophilic reaction one in Thermomixer
It fixes time, under the action of enzyme, connect connector with A base, product carries out purification and recovery with magnetic bead；
9) UNG digests bis- chain of cDNA: UNG digestion reaction system is prepared, two chains in double-stranded DNA are fallen by UNG enzymic digestion,
And purification and recovery is carried out to product with magnetic bead；
10) PCR reaction and product recycling: PCR reaction system is prepared, PCR response procedures appropriate is selected, upper step is obtained
To product expanded, to PCR product carry out magnetic beads for purifying recycling, recovery product is dissolved in EB solution, labelled.
11) Library Quality detects: using Agilent 2100Bioanalyzer and ABI StepOnePlusReal-Time
PCR System detects Library Quality；
12) machine is sequenced on: detecting qualified library, NaOH denaturation is added at single-stranded, it is anticipated that upper machine data volume, dilution
To certain upper machine concentration.Library after denaturation dilution is added in FlowCell, is hybridized with the connector on FlowCell,
Bridge-type PCR amplification is completed on cBot, is finally sequenced using IlluminaHiseq x-ten platform.
4, bioinformatic analysis
1) with cutadapt to the 5 ' of reads and 3 ' Duan Jinhang trim, trim falls the base of quality < 20, and it is big to delete N
In 10% reads；
2) hisat2 is compared onto reference genome.With reference to genome from Ensembl database, genome version
GRCh38, gene annotation information are Ensemble 92；
3) stringtie quantifies the expression quantity and normalization output of lncRNA；
4) edgeR packet compares control group with the differential expression of disease group lncRNA, the screening criteria of variances movement lncRNA
It is | log2FC |>1 and pvalue<0.05.
5, result
Sequencing data is as shown in table 2, and bioinformatic analysis discovery, LINC01522 is expressed significantly in patient with breast cancer
Up-regulation prompts LINC01522 to can be used as the early diagnosis that possible detection target is applied to breast cancer.
2 sequencing data of table
The differential expression of 2 QPCR sequence verification LINC01522 gene of embodiment
1, according to 25 luminal Type B breast cancer patients tissue samples of the collection mode collection of embodiment 1 and just
Normal tissue samples carry out large sample QPCR verifying to LINC01522 gene differential expression.
2, RNA is extracted
Tissue RNA is extracted using Trizol method, specific steps are referring to embodiment 1.
3, it reverse transcription: is operated using the reverse transcription reagent box (Takara code:DRR047A) of TAKARA company.
1) genomic DNA is removed
5 × gDNA Eraser B μ ffer, 2.0 μ l, gDNA Eraser1.0 μ l is added in test tube, 1 μ g of total serum IgE adds
Rnase Free ddH2O makes total volume to 10 μ l, 42 DEG C of heating 2min in water-bath.
2) reverse transcription reaction
It will24.0 μ l of Buffer,RT Enzyme Mix I1.0 μ l,
RTPrimer Mix1.0 μ l, RNase Free ddH24.0 μ l of O, which is added in above-mentioned test tube, is mixed together totally 20 μ l, in water-bath
37 DEG C of 15min, 85 DEG C of 5s.
4, QPCR is expanded
1) design of primers
According to the gene order design primer of LINC01522 and GADPH, specific primer sequence is as follows:
LINC01522 gene:
Forward primer is 5 '-CAACATCAACAGGACAAG-3 ' (SEQ ID NO.1)；
Reverse primer is 5 '-GTTCTCATTCTCCATCTTC-3 ' (SEQ ID NO.2).
GAPDH gene:
Forward primer is 5 '-AATCCCATCACCATCTTCCAG-3 ' (SEQ ID NO.3)；
Reverse primer is 5 '-GAGCCCCAGCCTTCTCCAT-3 ' (SEQ ID NO.4).
2) QPCR amplification is examined
WithPremix Ex TaqTMII (Takara Code:DRR081) kit configures PCR reaction system,
Thermal Cycler PCR amplification is carried out on Real Time System amplification instrument, confirms Real after reaction
The amplification curve and solubility curve of Time PCR, Δ Δ CT method carry out relative quantification.
Configure 25 μ l reaction systems:
Premix Ex TaqTM II (2 ×) 12.5 μ l, it is positive (anti-) to go out to each 1 μ l of primer, 2 μ l of DNA profiling
8.5 μ l of bacterium distilled water.
Reaction condition: 95 DEG C of 30s, (95 DEG C of 5s, 60 DEG C of 30s) × 40
5, result
QPCR result is as shown in Figure 1, compared with normal tissue, and LINC01522 is raised in expression in breast, difference
It is consistent with high-flux sequence result with statistical significance (P < 0.05), prompt LINC01522 to can be used as biomarker application
In the diagnosing and treating of breast cancer, namely the level by detecting LINC01522 may determine that whether subject suffers from breast cancer,
When the level of LINC01522 dramatically increases, subject is with breast cancer or there is the risk for suffering from breast cancer, passes through
Relationship between LINC01522 and breast cancer can design shRNA, siRNA of targeting LINC01522 to treat breast cancer.
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Sequence table
<110>People's Hospital of Deyang City
<120>a kind of lncRNA marker relevant to breast cancer
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
caacatcaac aggacaag 18
<210> 2
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
gttctcattc tccatcttc 19
<210> 3
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
aatcccatca ccatcttcca g 21
<210> 4
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
gagccccagc cttctccat 19
Claims (10)
1.LINC01522 application, which is characterized in that be used to prepare the product of Diagnosis of Breast cancer.
2. application according to claim 1, which is characterized in that the product includes LINC01522 expression in detection sample
Horizontal reagent.
3. application according to claim 2, which is characterized in that the reagent includes passing through reverse transcription PCR, real-time quantitative
PCR, in situ hybridization, chip technology detection LINC01522 expression reagent.
4. application according to claim 1-3, which is characterized in that the breast cancer is Luminal Type B mammary gland
Cancer.
5. a kind of product of Diagnosis of Breast cancer, which is characterized in that including chip or kit, wherein the chip or kit
Reagent including detecting LINC01522 expression.
6. product according to claim 5, which is characterized in that detect the reagent packet of LINC01522 expression in chip
Include the probe of specific recognition LINC01522 gene；The reagent that LINC01522 expression is detected in kit includes specificity
Expand the primer of LINC01522 gene or the probe of specific recognition LINC01522 gene.
7. product according to claim 6, which is characterized in that the primer sequence of specific amplification LINC01522 gene is such as
Shown in NO.1~2 SEQ ID.
8.LINC01522 application, which is characterized in that for construct prediction breast cancer computation model.
9.LINC01522 application, which is characterized in that for screen treatment breast cancer drug candidate.
10.LINC01522 application, which is characterized in that be used to prepare treatment breast cancer pharmaceutical composition.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910298612.6A CN109913554A (en) | 2019-04-15 | 2019-04-15 | A kind of lncRNA marker relevant to breast cancer |
| CN201911075429.6A CN110628913B (en) | 2019-04-15 | 2019-11-06 | lncRNA marker related to breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910298612.6A CN109913554A (en) | 2019-04-15 | 2019-04-15 | A kind of lncRNA marker relevant to breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109913554A true CN109913554A (en) | 2019-06-21 |
Family
ID=66969817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910298612.6A Pending CN109913554A (en) | 2019-04-15 | 2019-04-15 | A kind of lncRNA marker relevant to breast cancer |
| CN201911075429.6A Active CN110628913B (en) | 2019-04-15 | 2019-11-06 | lncRNA marker related to breast cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911075429.6A Active CN110628913B (en) | 2019-04-15 | 2019-11-06 | lncRNA marker related to breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN109913554A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111118146A (en) * | 2020-02-10 | 2020-05-08 | 山东大学齐鲁医院(青岛) | Application of LncRNA in diagnosis of breast cancer chemotherapy-related myocardial injury patient |
| CN116312785A (en) * | 2023-01-19 | 2023-06-23 | 首都医科大学附属北京胸科医院 | Breast cancer diagnosis marker gene and screening method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117604110B (en) * | 2024-01-23 | 2024-04-19 | 杭州华得森生物技术有限公司 | Biomarker for breast cancer diagnosis and prognosis and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10801072B2 (en) * | 2014-09-04 | 2020-10-13 | Miodx | Method of analysis allowing avoidance of surgery |
| US11175286B2 (en) * | 2015-01-09 | 2021-11-16 | Spot Biosystems Ltd. | Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles |
| CN109563549B (en) * | 2016-06-03 | 2023-07-14 | 新加坡保健服务集团有限公司 | Genetic variation in antisense long non-coding RNAs as biomarkers of sensitivity to disease treatment |
| CN107267606A (en) * | 2017-04-20 | 2017-10-20 | 浙江理工大学 | A kind of lncRNA and its application in lung cancer detection label or prognosis recurrence label is merged as breast cancer |
-
2019
- 2019-04-15 CN CN201910298612.6A patent/CN109913554A/en active Pending
- 2019-11-06 CN CN201911075429.6A patent/CN110628913B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111118146A (en) * | 2020-02-10 | 2020-05-08 | 山东大学齐鲁医院(青岛) | Application of LncRNA in diagnosis of breast cancer chemotherapy-related myocardial injury patient |
| CN116312785A (en) * | 2023-01-19 | 2023-06-23 | 首都医科大学附属北京胸科医院 | Breast cancer diagnosis marker gene and screening method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110628913A (en) | 2019-12-31 |
| CN110628913B (en) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102369294B (en) | Non-small cell lung cancer detection marker, detection method thereof, related reagent kit and biochip | |
| US20190241966A1 (en) | Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples | |
| CN104981548A (en) | Diagnostic mirna markers for alzheimer | |
| CN101942502A (en) | Pancreatic cancer marker, and detection method, kit and biochip thereof | |
| CN109609648A (en) | LncRNA marker relevant to liver cancer and its detection primer and application | |
| CN109913554A (en) | A kind of lncRNA marker relevant to breast cancer | |
| CN104968802A (en) | Novel miRNAs as diagnostic markers | |
| CN104975019B (en) | Application of the finger-print of tiny RNA composition in human ovarian cancer diagnosing and treating | |
| CN104673883B (en) | For predicting the microRNA biomarker and detection method of early stage non-metastatic colorectal cancer prognosis | |
| CN111187840B (en) | Biomarker for early breast cancer diagnosis | |
| CN110714080B (en) | Biomarkers for diagnosis and treatment of breast cancer | |
| CN110257516A (en) | For developing molecular marker and the application of diagnosing gastric cancer product | |
| CN102399870B (en) | Reagent for determining survival and prognosis of patients with esophagus cancer | |
| CN110628914B (en) | LncRNA marker related to breast cancer, detection primer and application thereof | |
| CN110452989B (en) | Application of biomarker in detection and diagnosis of gastric cancer | |
| US20150329911A1 (en) | Nucleic acid biomarkers for prostate cancer | |
| CN105603117B (en) | MiR-3613 is used to distinguish lung squamous cancer transfer and non-diverting miRNA marker | |
| CN105821131B (en) | Osteosarcoma miRNA marker | |
| CN110055333A (en) | Application of the RP11-116O18.1 as molecular marker in lung cancer | |
| CN109913552A (en) | A kind of esophageal squamous cell carcinoma diagnosis and treatment target spot and application | |
| CN110592219A (en) | lncRNA diagnosis and treatment marker for breast cancer | |
| CN109439743A (en) | A kind of biomarker of severe asthma and its application | |
| CN110117656A (en) | A kind of biomarker relevant to sdenocarcinoma of stomach occurrence and development | |
| CN109628598A (en) | Application of the long-chain non-coding RNA in tumour | |
| CN109825594A (en) | Application of the biomarker in breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190621 |
|
| WD01 | Invention patent application deemed withdrawn after publication |